Related Experiment Video
Updated: Jun 15, 2026
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Genotoxicity of anti-tumor necrosis factor therapy in patients with juvenile idiopathic arthritis
Erkan Demirkaya1, Ismet Cok, Emre Durmaz
1Hacettepe University Medical School, Ankara, Turkey. dottore_erkan@yahoo.com
Objective:
To assess the possible effects of both inflammation and the anti-tumor necrosis factor agents (anti-TNF) on DNA damage with a specific assay, and their effects on the repair capacity of DNA.
Methods:
From a group of 20 children with juvenile idiopathic arthritis (JIA), 16 patients who completed the study and 16 control subjects were evaluated. DNA damage and repair capacity were analyzed by the comet assay at the level of peripheral lymphocytes before anti-TNF (etanercept) injections and on the 15th, 90th, and 180th days after the first injection.
Results:
The amount of damage as detected by the aforementioned assay was higher in patients with JIA compared with controls. On the 15th day after the initial anti-TNF injection, there was a decrease in the mean DNA tail length of JIA patients, however on the 90th day an increase was observed; thereafter, an upward trend was observed until the end of the study. JIA patients had a DNA repair capacity that was significantly less than that of controls.
Conclusion:
The results of the comet technique suggests that JIA patients already have increased basal DNA damage before anti-TNF therapy; they are more sensitive to the DNA damage produced by H(2)O(2), and have a less efficient DNA repair system in comparison with control cells. After an initial improvement at 2 weeks, parameters of genotoxicity worsened, and DNA repair was further impaired 6 months after the addition of an anti-TNF agent to treatment.
Insights
Juvenile idiopathic arthritis (JIA) patients exhibit increased DNA damage and impaired repair. Anti-tumor necrosis factor (anti-TNF) therapy initially improved DNA damage but worsened it over six months, further impairing repair capacity.
Area of Science:
- Genetics and Molecular Biology
- Immunology
- Pediatric Rheumatology
Background:
- Juvenile idiopathic arthritis (JIA) is an autoimmune condition characterized by inflammation.
- Anti-tumor necrosis factor (anti-TNF) agents are used to treat JIA, but their impact on DNA integrity is not fully understood.
Purpose of the Study:
- To evaluate DNA damage and repair capacity in children with JIA.
- To assess the effects of anti-TNF therapy on DNA damage and repair.
Main Methods:
- The comet assay was used to analyze DNA damage and repair in peripheral lymphocytes of 16 JIA patients and 16 controls.
- Samples were collected before and at 15, 90, and 180 days after initiating etanercept (an anti-TNF agent).
Main Results:
- JIA patients showed higher basal DNA damage and reduced DNA repair capacity compared to controls.
- Anti-TNF therapy initially decreased DNA tail length (indicating less damage) by day 15.
- DNA damage increased by day 90 and showed an upward trend thereafter, with further impaired DNA repair observed at 6 months.
Conclusions:
- JIA is associated with increased DNA damage and deficient DNA repair mechanisms.
- While anti-TNF therapy may offer initial genoprotective effects, long-term treatment appears to exacerbate DNA damage and impair repair capacity in JIA patients.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Teratogenicity
